Lyon, France – (BUSINESS WIRE) – Regulatory news:
ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides, announced today at the 14th Technologies and Treatments for Diabetes (ATTD 2021), which will take place from Jan. takes place as a virtual event until June 5, 2021.
Below you will find detailed information about the presentation:
About ATTD
ATTD is a scientific program that brings together renowned international experts to discuss key advances in diabetes treatment, technological innovations and the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed systems and more.
About Adocia
Adocia is a clinical-stage biotechnology company specializing in developing innovative formulations of therapeutic proteins and peptides for the treatment of diabetes, obesity and metabolic diseases. In diabetes, Adocia’s injectable treatments portfolio is one of the largest and most diverse in the industry, with five clinical-stage products and several pre-clinical products. The proprietary BioChaperone® technology platform is designed to improve the efficacy and / or safety of therapeutic proteins while making them easier to use for patients. Adocia adapts BioChaperone to each protein for a specific application.
Adocia’s clinical pipeline includes four novel insulin formulations for the prandial treatment of diabetes: two ultra-fast formulations of the insulin analogue Lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and fast-acting insulin Lispro (BioChaperone® Combo), and a combination of a prandial Insulins with the amylin analogue pramlintide M1Pram. The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia.
Adocia’s preclinical pipeline includes bihormonal combinations for the treatment of diabetes: two combinations of fast-acting insulin analogues and pramlintide (BioChaperone® Lispro Pram and BioChaperone® Aspart Pram), a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). There are also two bihormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone® Glucagon Exenatide) and a combination of pramlintide and exenatide (PramExe).
Adocia recently added a preclinical program with a cell therapy initiative focused on developing a hydrogel scaffold for people with type 1 diabetes. The first patent application in support of this program has been filed.
Disclaimer of liability
This press release contains certain forward-looking statements about Adocia and its business. Such forward-looking statements are based on assumptions that Adocia believes to be appropriate. However, there can be no assurance that the estimates made in any such forward-looking statement will be verified as such estimates are subject to numerous risks, including those set out in the “Risk Factors” section of the universal registration document filed with the French Authorité des marchés financiers on March 20 April 2021 (a copy of which is available at www.adocia.com) and on developments in the economic conditions of the financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks that Adocia is not yet aware of or that Adocia does not currently consider to be material. The occurrence of all or some of these risks could cause the actual results, financial conditions, performance or achievements of Adocia to differ materially from such forward-looking statements. This press release and the information contained herein constitute neither an offer to sell nor a solicitation of an offer to buy Adocia shares in any jurisdiction.
